WO1999010001A1 - Agents cancerostatiques - Google Patents
Agents cancerostatiques Download PDFInfo
- Publication number
- WO1999010001A1 WO1999010001A1 PCT/JP1998/003697 JP9803697W WO9910001A1 WO 1999010001 A1 WO1999010001 A1 WO 1999010001A1 JP 9803697 W JP9803697 W JP 9803697W WO 9910001 A1 WO9910001 A1 WO 9910001A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- mbp
- amino acid
- protein
- mannan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a drug useful in the field of medicine, which suppresses cancer growth by increasing the concentration of a specific protein in cancer cells, surrounding tissues or non-affected tissues.
- animal lectins proteins that recognize sugars other than immunoglobulins, such as blood group recognition antibodies.
- the mannan-binding protein may be called mannose-binding protein or mannan bindingin.
- serum MBP does not depend on antibodies or the complement component C1 ⁇ , It activates the complement system through the pathway. Furthermore, serum MBP is known to have a direct biological defense effect. For example, to suppress infection by binding to high mannose-type sugar chains on the envelope glycoprotein of the human immunodeficiency virus, or to promote phagocytic removal of yeast and certain gram-negative bacteria. It has been known.
- An object of the present invention is to provide a drug that suppresses the growth of cancer in cancer cells, its surrounding tissues or non-affected tissues.
- the present inventors have conducted various studies on the structure and function of MBP in order to achieve the above object, and surprisingly, surprisingly, a tumor-bearing animal to which a gene encoding MBP was administered and The present inventors found that the ability of cancer-bearing animals to which a gene encoding MBP was administered was clearly inhibited from growing with cancer-bearing animals to which the gene encoding the gene was not administered. completed.
- the present invention relates to an anticancer agent comprising a mannan-binding protein or a gene thereof as an active ingredient.
- FIG. 1 is a diagram showing a restriction enzyme map of vaccinia virus vector pBSF2-16.
- FIG. 2 is a diagram showing a schematic diagram of the MBP expression plasmid pBSF2- 16 / MBP.
- FIG. 3 shows the results of an in vivo anticancer effect evaluation experiment.
- MBP refers to not only natural MBP but also amino acid residue substitution, deletion, addition, It is meant that the present invention also includes proteins whose amino acid sequence has been modified by insertion or the like.
- MBP human derived protein kinase
- examples of the natural MBP herein include those derived from humans or egrets, but are not limited to these in the present invention, and include those derived from organisms such as other animals and plants.
- those derived from microorganisms such as bacteria, yeasts, actinomycetes, filamentous fungi, ascomycetes, and basidiomycetes are also included.
- the gene encoding MBP is not particularly limited as long as it encodes the above-mentioned MBP and a protein having MBP activity. Even a gene that has been subjected to a mutation treatment such as substitution, deletion, addition, or insertion is included in the present invention as long as it is a gene that encodes a protein having MBP activity.
- the object can be achieved by introducing MBP into cancer cells, surrounding tissues or non-affected tissues.
- MBP MBP may be introduced directly into the cancer cells while retaining the activity of the MBP, for example, by direct injection into the cancer cells, such as microinjection, or subcutaneous administration It may be introduced by the method or intravenous administration while maintaining the MBP activity.
- a gene encoding MBP may be introduced into cancer cells using a virus or the like, or a gene encoding MBP may be introduced into cancer cells by a subcutaneous administration method, etc.
- the object of the present invention can be achieved by expressing P.
- MBP or a gene encoding MBP can be introduced into cancer cells, surrounding tissues or non-affected tissues, and cancer growth can be suppressed.
- MBP or the gene encoding MBP may be directly injected into the affected area on the tissue surface or the surrounding tissue.
- the drug can be injected directly into the affected area inside the tissue and the surrounding tissue, but a drug delivery system (DDS) can also be applied.
- DDS drug delivery system
- Any system can be used as the DDS as long as it is a system specific to cancer cells.
- a general system using a cancer cell receptor, a cancer-specific antibody, or the like may be selected.
- MBP can be specifically introduced into specific organs or cells of the surrounding tissue by using a specific receptor or receptor receptor.
- cancer tissue It is also an extremely effective method to suppress the growth of micro-cancer by surgically removing the same and then applying the agent of the present invention to the non-cancer part.
- the anticancer agent of the present invention only needs to contain MBP or a gene encoding MBP within a pharmaceutically acceptable range, and can be formulated as ordinary gene therapeutics and protein-containing agents.
- the preparation may contain carriers, excipients, stabilizers, thickeners and the like.
- the dosage of MBP or the gene encoding MBP used as the anticancer agent of the present invention depends on the form of the preparation, the method of use and the age, weight, disease progression, etc. of the patient using the drug. It may be set and adjusted as appropriate after taking into account. For example, in the case of protein, it is 0.01 g to lg / kg per adult. Also, when using the recombinant virus protein expression, using adult once per lxl 0 2 ⁇ lxl 0 12 PFU of (plaque forming units). Naturally, the amount used varies depending on various conditions, and therefore, there are cases where an amount smaller than the above amount is sufficient, or where the amount exceeds the range.
- MBP or the gene encoding MBP contained in the anticancer agent of the present invention is an in vivo substance and has no toxicity.
- Sepharose 4 B Mannan 1 19.7 4.5
- the binding activity of MBP was determined by the method described in Journal of Biochemistry, Vol. 94, No. 3, pp. 937-947 (1983), in accordance with the method described in I-mannan labeled with 125 I. Can be measured. Specific activity of the MB P is expressed in bound '25 I- mannan (ng) / protein amounts ( ⁇ G). The protein mass is determined by the Lori method using bovine serum albumin as a standard.
- the gene encoding MBP can be obtained, for example, from a human liver cDNA library by the method of Kurata et al. [Journal of Biochemistry, Vol. 115, No. 6, No. 1148-: 1154 (1994)]. it can.
- amino acid sequence of the mature protein of human MBP obtained by this method is shown in SEQ ID NO: 1 in the sequence listing, and the nucleotide sequence of the gene encoding them is shown in SEQ ID NO: 2 in the sequence listing.
- a gene that hybridizes to the gene and encodes a protein having MBP activity can be prepared.
- a gene encoding a protein having MBP activity can be prepared by designing a primer from these genes or a part thereof and performing a PCR reaction using the primers.
- a hybridization method for example, a Nymouth membrane on which a genomic DNA or cDNA library obtained from an organism or a microorganism is immobilized is prepared, and 0.5% SDS, 5X Denhalt [Denhardt, s, 0.1% serum albumin
- BSA 0.1% polyvinylpyrrolidone, 0.1% ficoll 400] 10 salmon sperm DNA and 6XSSC (Ix SSC is 0.15M NaCl, 0.015M sodium citrate, pH7 Block the nylon membrane in a prehybridization solution containing .0) at 65 ° C. Then, add each probe labeled with “P” and incubate at 65 ° C for 4 hours to 1 hour. This nylon membrane is incubated in 6 x SSC at room temperature for 10 minutes, in 0.1% SDS at 45 ° C. After 30 minutes of washing with DNA, the DNA that hybridizes with the probe can be detected by photoradiography, and the genes showing various homology can be obtained by changing washing and other conditions. Can be.
- the gene represented by SEQ ID NO: 2 in the Sequence Listing can also be represented by SEQ ID NO: 2 by performing genetic engineering substitution, deletion, addition, insertion, etc.
- a gene that hybridizes to a gene and encodes a protein having MBP activity can be prepared.
- Examples of the method for performing the mutation treatment include a method using an amber mutation [gapped duplex method, Nucleic Acids Research, Vol. 12, No. 24, No. 9441-9456]. page
- Whether the gene thus obtained is a gene encoding a protein having MBP activity can be determined by Journal of Biochemistry, Vol. 94, No. 3, pp. 937-947 (1983) or Journal This can be confirmed by measuring the MBP activity according to the method described in "Biochemistry", Vol. 115, No. 6, No. 1 148-114 (1994).
- genes and expressed proteins obtained by the genes can also be used as the drug of the present invention.
- a recombinant vector having a gene encoding MBP and a regulatory gene related thereto must be used.
- regulatory genes besides the promoter of the gene encoding MBP itself, of course, other effective promoters such as vaccinia Lus A inclusion body (ATI) Promote overnight, SV40 Promo overnight, Retrovirus-derived LTR Promo overnight, Heat shock promoter, Meta-mouth Thionein Promo overnight, Actin Promo overnight Vectors can be used.
- ATI vaccinia Lus A inclusion body
- Retrovirus-derived LTR Promo overnight Retrovirus-derived LTR Promo overnight
- Heat shock promoter Meta-mouth Thionein Promo overnight
- Actin Promo overnight can be used These vectors can be introduced into cancer or non-cancerous cells in the form of vectors that remain extrachromosomal in the cell.
- the gene can be expressed by the cell from an extrachromosomal location, produce MBP, increase the intracellular MBP concentration, and achieve the object of the present invention.
- Extrachromosomal vectors are known in the art, and appropriate vectors are used.
- electroporation, calcium phosphate coprecipitation, virus transduction, and the like are known in the art. Range.
- the gene encoding MBP can be introduced into a cancer or a cell that has not yet become cancerous, in the form of a vector that integrates the gene into the chromosome. In such a state, the gene can be retained in the chromosome, expressed by the cell, produce MBP, increase the MBP concentration in the cell, and achieve the object of the present invention.
- a vector containing the gene By using a viral vector to introduce the MBP gene into cells, a vector containing the gene can be efficiently introduced.
- These vectors have been known to transport the target DNA into cells, and have high infection efficiency, such as vaccinia virus vector, retrovirus vector, adenovirus vector, adeno-associated virus vector, or the like.
- a non-proliferating recombinant virus vector or the like can be used. In particular, it is necessary to use a non-proliferating recombinant virus vector every 2 weeks to 2 months after introduction into a target cell, etc., in order to prevent the propagation of this recombinant virus.
- vaccinia virus vector pBSF2-16 (Fig. 1) was constructed from the human MBP cDNA by the method described in Archives of Virology, Volume 138, pp. 315-330 (199).
- MBP recombinant vector pBSF2-l6 / MBP Figure 2
- This recombinant vector pBSF2-16 / MBP and wild-type vaccinia virus DNA are cotransfected into COS-7 cells, and the resulting recombinant vaccinia virus is transformed into, for example, a hemagglutinin phenotype or MBP.
- an MBP-expressing recombinant hexinia virus can be obtained.
- the agent of the present invention is administered, and the subsequent growth potential of the cancer tissue is measured to evaluate the anti-cancer effect.
- Can be That is, the human colon cancer cell line SW1116 is inoculated subcutaneously into KSN nude mice, and three weeks later, the above-described recombinant recombinant vaccinia virus expressing MBP is administered intratumorally or subcutaneously in a non-affected area. Two weeks later, the recombinant vaccinia virus expressing MBP is once again administered in the same manner, and the tumor size after administration can be measured to evaluate the ability to suppress the growth of cancer cells.
- a cDNA clone H—3-1 containing the entire coding region of human MBP [Ja-Naruob Biochemistry, Vol. 115, No. 6, pp. 1148-115 (1994)] was vaccinia virus Vector pB SF 2-16 Ivsov virology, Vol. 138, pp. 315-330 (1994)], the ATI hybrid promoter (with several 7.5 kDa promoters arranged in series and the ATI promoter).
- the clone was subcloned into the Smal and Sac1 sites to prepare an MBP expression plasmid pBSF2_16 / MBP controlled by the ATI hybrid promoter.
- FIG. 1 shows a restriction map of the vaccinia virus vector pBSF2-16.
- FIG. 2 shows a schematic diagram of the MBP expression plasmid pBSF2-16ZMBP.
- the IBT (isatin-/?-Thiosemicarbazone) -dependent vaccinia virus strain [Virology, Vol. 155, No. 97-: L 05 (1986)] was transformed into ⁇ 03-7 cells (Haccho).
- ⁇ CRL 1651 The COS-7 cells infected with the IBT-dependent vaccinia virus strain were infected with pBSF2-16 / MBP and genomic DNA extracted from virions of the wild-type vaccinia virus strain WR. was introduced using DOTAP reagent (manufactured by Behringer Mannheim) to produce an MBP recombinant vaccinia virus.
- Recombinant vaccinia virus was selected by the hemagglutinin phenotype according to the method described in Archives Subvirology, Vol. 138, pp. 315-330 (1994), and was selected by ELISA in RK-13 cells (ATCC CCL37). Detected. Viral activity was measured by the plaque forming method and expressed as plaque forming units (PFU).
- the evaluation of the anti-cancer effect in vivo was performed as follows.
- Human colon cancer cell line SW1116 (ATCC CCL233) was inoculated subcutaneously into KSN nude mice (manufactured by Nippon SLC Co., Ltd.) at a dose of 10 'per mouse.
- the MBP recombinant described in Example 1 was used.
- the vaccinia virus was administered mice one animal per 5x l O E PFU intratumoral of the affected part, or the non-affected area subcutaneously.
- the same amount of the wild-type vaccinia virus WR strain was administered into the affected tumor.
- the same amount of the MBP recombinant vaccinia virus or wild-type vaccinia virus WR strain was administered again in the same manner, and the size of the tumor after administration was measured. The ability to suppress cell growth was evaluated.
- FIG. 3 is a diagram showing the results of an in vivo anticancer effect evaluation experiment, in which the vertical axis represents tumor size (mm) and the horizontal axis represents the number of weeks after cancer cell transplantation.
- the black squares indicate the group to which saline was administered subcutaneously in the non-affected area
- the white circles indicate the group to which the wild-type vaccinia virus WR strain was administered into the tumor of the affected area
- the black circles indicate the MBP group.
- the group where the recombinant vaccinia virus was administered into the tumor of the affected area is shown, and the black triangle indicates the group where the MBP recombinant vaccinia virus was administered subcutaneously to the non-affected area.
- the arrows in the figure indicate the week of administration of MBP vaccinia virus, wild-type vaccinia virus WR strain, and physiological saline, respectively.
- a carcinostatic agent characterized by enhancing the MBP concentration of a surrounding tissue or a non-affected tissue in a cancer cell, that is, comprising MBP or a gene thereof as an active ingredient.
- the anticancer agent is useful in the field of cancer treatment. Sequence Listing SEQ ID NO: 1
- Sequence type nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69836428T DE69836428T2 (de) | 1997-08-21 | 1998-08-19 | Karzinostatische wirkstoffe |
AU87481/98A AU8748198A (en) | 1997-08-21 | 1998-08-19 | Carcinostatic agents |
JP51416599A JP3990736B2 (ja) | 1997-08-21 | 1998-08-19 | 制がん剤 |
KR10-2000-7000331A KR100497849B1 (ko) | 1997-08-21 | 1998-08-19 | 제암제 |
EP98938917A EP1008351B1 (en) | 1997-08-21 | 1998-08-19 | Carcinostatic agents |
US09/971,475 US7410953B2 (en) | 1997-08-21 | 2001-10-04 | Anticancer agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/239113 | 1997-08-21 | ||
JP23911397 | 1997-08-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US46870599A Continuation | 1997-08-21 | 1999-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999010001A1 true WO1999010001A1 (fr) | 1999-03-04 |
Family
ID=17039998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003697 WO1999010001A1 (fr) | 1997-08-21 | 1998-08-19 | Agents cancerostatiques |
Country Status (9)
Country | Link |
---|---|
US (1) | US7410953B2 (ja) |
EP (1) | EP1008351B1 (ja) |
JP (1) | JP3990736B2 (ja) |
KR (1) | KR100497849B1 (ja) |
CN (1) | CN1106846C (ja) |
AT (1) | ATE345139T1 (ja) |
AU (1) | AU8748198A (ja) |
DE (1) | DE69836428T2 (ja) |
WO (1) | WO1999010001A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6148198A (en) * | 1998-08-05 | 2000-11-14 | Ericsson Inc. | Method and apparatus for selecting a service provider |
US6562784B1 (en) | 1999-05-14 | 2003-05-13 | Steffen Thiel | Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
WO2004024925A2 (en) * | 2002-09-10 | 2004-03-25 | Natimmune A/S | Collectin-complement activating protein chimeras |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324046C (zh) * | 2004-11-24 | 2007-07-04 | 中国科学院大连化学物理研究所 | 一种具有抗hiv活性的蛋白和糖结合蛋白 |
DE602005026705D1 (de) * | 2004-12-23 | 2011-04-14 | Council Scient Ind Res | Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose |
PT2347775T (pt) | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
DK2624873T3 (da) | 2010-10-06 | 2020-03-02 | Harvard College | Injicerbare, pore-dannende hydrogeler til materiale-baserede celleterapier |
LT2838515T (lt) | 2012-04-16 | 2020-03-10 | President And Fellows Of Harvard College | Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui |
JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN107708756A (zh) | 2015-04-10 | 2018-02-16 | 哈佛学院院长等 | 免疫细胞捕获装置及其制备和使用方法 |
CN109072197A (zh) | 2016-02-06 | 2018-12-21 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
WO2017143024A2 (en) | 2016-02-16 | 2017-08-24 | President And Fellows Of Harvard College | Pathogen vaccines and methods of producing and using the same |
BR112018070022A2 (pt) | 2016-03-30 | 2019-02-05 | Ab biosciences inc | composições de imunoglobulina intravenosa recombinante (rivig) e métodos para sua produção e uso |
CA3030427A1 (en) | 2016-07-13 | 2018-01-18 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62205034A (ja) * | 1986-02-21 | 1987-09-09 | オンコ−ゲン | 生物活性抗腫瘍抗体による腫瘍療法 |
JPH02504581A (ja) * | 1987-08-20 | 1990-12-27 | チルドレンズ・ホスピタル・コーポレイション | ヒトマンノース結合タンパク質 |
US5270199A (en) * | 1987-08-20 | 1993-12-14 | The Children's Medical Center Corporation | Human mannose-binding protein |
JPH06501620A (ja) * | 1990-11-06 | 1994-02-24 | ザ・チルドレンズ・メディカル・センター・コーポレイション | 可溶性マンノース受容体ペプチド |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5091178A (en) * | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
AU734196B2 (en) * | 1996-03-28 | 2001-06-07 | Whitehead Institute | Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
ES2272067T3 (es) * | 1998-06-10 | 2007-04-16 | Statens Serum Institut | Procedimiento de purificacion para la produccion de lecitina de union a manano y un producto medicinal de mbl. |
-
1998
- 1998-08-19 WO PCT/JP1998/003697 patent/WO1999010001A1/ja active IP Right Grant
- 1998-08-19 AT AT98938917T patent/ATE345139T1/de not_active IP Right Cessation
- 1998-08-19 KR KR10-2000-7000331A patent/KR100497849B1/ko not_active IP Right Cessation
- 1998-08-19 AU AU87481/98A patent/AU8748198A/en not_active Abandoned
- 1998-08-19 DE DE69836428T patent/DE69836428T2/de not_active Expired - Fee Related
- 1998-08-19 CN CN98808243A patent/CN1106846C/zh not_active Expired - Fee Related
- 1998-08-19 EP EP98938917A patent/EP1008351B1/en not_active Expired - Lifetime
- 1998-08-19 JP JP51416599A patent/JP3990736B2/ja not_active Expired - Fee Related
-
2001
- 2001-10-04 US US09/971,475 patent/US7410953B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62205034A (ja) * | 1986-02-21 | 1987-09-09 | オンコ−ゲン | 生物活性抗腫瘍抗体による腫瘍療法 |
JPH02504581A (ja) * | 1987-08-20 | 1990-12-27 | チルドレンズ・ホスピタル・コーポレイション | ヒトマンノース結合タンパク質 |
US5270199A (en) * | 1987-08-20 | 1993-12-14 | The Children's Medical Center Corporation | Human mannose-binding protein |
JPH06501620A (ja) * | 1990-11-06 | 1994-02-24 | ザ・チルドレンズ・メディカル・センター・コーポレイション | 可溶性マンノース受容体ペプチド |
Non-Patent Citations (4)
Title |
---|
FUJITA T. et al., "Mannose-Binding Protein Recognizes Glioma Cells: In Vitro Analysis of Complement Activation on Glioma Cells Via the Lectin Pathway", JPN. J. CANCER RES., 86, 1995, pp. 187-192. * |
KUNIO YAGI, "Cationic Liposomes (in Japanese)", "Gene Therapy (in Japanese)", PROTEIN, NUCLEIC ACID AND ENZYME, Special Extra Issue, Vol. 40, No. 17, 1995, pp. 2577-2582. * |
MOLECULAR BIOLOGY OF CELLS, 2nd Ed., (in Japanese), Supervised by KEIKO NAKAMURA, KENICHI MATSUBARA, KYOIKUSHA, 1990, pp. 1031-1036. * |
SASTRY K. et al., "The Human Mannose-Binding Protein Gene", J. EXP. MED., 170, 1989, pp. 1175-1189. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6148198A (en) * | 1998-08-05 | 2000-11-14 | Ericsson Inc. | Method and apparatus for selecting a service provider |
US6562784B1 (en) | 1999-05-14 | 2003-05-13 | Steffen Thiel | Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
US6846649B1 (en) | 1999-05-14 | 2005-01-25 | Steffen Thiel | Recombinant human mannan-binding lectin |
US7202207B2 (en) | 1999-05-14 | 2007-04-10 | Steffen Thiel | Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
US7439224B2 (en) | 1999-05-14 | 2008-10-21 | Steffen Thiel | Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromised individuals |
WO2004024925A2 (en) * | 2002-09-10 | 2004-03-25 | Natimmune A/S | Collectin-complement activating protein chimeras |
WO2004024925A3 (en) * | 2002-09-10 | 2004-06-24 | Natimmune As | Collectin-complement activating protein chimeras |
Also Published As
Publication number | Publication date |
---|---|
EP1008351A4 (en) | 2004-11-10 |
EP1008351B1 (en) | 2006-11-15 |
KR100497849B1 (ko) | 2005-06-29 |
US20020086817A1 (en) | 2002-07-04 |
US7410953B2 (en) | 2008-08-12 |
DE69836428D1 (de) | 2006-12-28 |
EP1008351A1 (en) | 2000-06-14 |
ATE345139T1 (de) | 2006-12-15 |
JP3990736B2 (ja) | 2007-10-17 |
CN1267223A (zh) | 2000-09-20 |
AU8748198A (en) | 1999-03-16 |
DE69836428T2 (de) | 2007-09-27 |
CN1106846C (zh) | 2003-04-30 |
KR20010021768A (ko) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999010001A1 (fr) | Agents cancerostatiques | |
AU2018265258B2 (en) | Enveloped virus resistant to complement inactivation for the treatment of cancer | |
JP4404479B2 (ja) | 血管内皮増殖因子の可溶性インヒビターおよびその使用 | |
EA022932B1 (ru) | Димерные слитые белки vstm3 и связанные с ними композиции и способы | |
US20020132774A1 (en) | Antagonists of neuropilin receptor function and use thereof | |
CN100558745C (zh) | 同种排斥反应的特异性抑制 | |
KR20050084473A (ko) | α-갈락토시다아제 A 결핍을 치료하는 방법 | |
CN112442129B (zh) | 肿瘤酶响应型重组焦亡蛋白递药系统及其抗肿瘤用途 | |
CN108440673B (zh) | Fc融合蛋白PD1/FGFR1及其应用 | |
CN111909246B (zh) | 高效感染支持细胞的aav突变体 | |
US20220233715A1 (en) | Aav mutant that efficiently infects supporting cells | |
US20040171111A1 (en) | Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof | |
US20070134229A1 (en) | Non-native constitutively active osteopontin | |
WO2021165841A1 (en) | Compound for the treatment of a glycogenosis | |
US6303289B1 (en) | Composition and methods for the treatment of cancer and viral infections | |
CA2347650A1 (en) | Transmembrane 4 proteins | |
CN115989238A (zh) | 包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途 | |
CN117899223A (zh) | 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物 | |
JP2000325087A (ja) | Tsa2306遺伝子 | |
JP4632326B2 (ja) | イヌのアトピー性皮膚炎の治療薬及び治療方法 | |
US20010029012A1 (en) | Composition and methods for the treatment of cancer and viral infections | |
CN101195657A (zh) | 一个i型细胞因子受体样分子及其编码基因与应用 | |
CN1401387A (zh) | 抑瘤多肽tsf及其基因治疗载体组合物 | |
WO2001030836A1 (fr) | Nouvelles atpases humaines et leurs sequences de codage | |
CN1297943A (zh) | 人脑表达的x染色体连锁蛋白及其编码序列 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98808243.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR MX NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007000331 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998938917 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998938917 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000331 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007000331 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998938917 Country of ref document: EP |